Are There Any Common Side Effects or Scalp Reactions to Watch For When Applying Pyrilutamide?

Understanding the potential side effects of pyrilutamide (KX-826) is essential for anyone considering its use. Because this medication is still under clinical investigation, publicly available evidence remains limited, fragmented, and largely derived from pharmaceutical filings, conference abstracts, and partial clinical disclosures. The sponsor describes a favorable safety profile, but these results need cautious interpretation. This article sets out what the public record shows about side effects, and what remains unclear.

Pyrilutamide is a topical androgen-receptor antagonist. In simple terms, androgens—particularly dihydrotestosterone (DHT)—bind to receptors in hair follicles and contribute to the gradual miniaturization characteristic of androgenetic alopecia. Pyrilutamide attempts to block that binding directly at the follicular level. Unlike oral anti-androgens, it aims to act mostly at the site of application. This local mechanism theoretically reduces systemic hormone disruption and lowers the risk of widespread side effects.

However, this theoretical advantage depends on how much of the drug is absorbed into the bloodstream. Early pharmacokinetic disclosures from Kintor Pharmaceutical suggest low systemic exposure, but without full peer-reviewed data, this assumption should be treated carefully.

What Clinical Trials Reveal: A Critical Look at Safety Data

A Phase I trial conducted in 2020 (NCT04502901) tested ascending topical doses of pyrilutamide in 40 healthy men with androgenetic alopecia. The study was randomized, double-blind, and placebo-controlled, a design that reduces bias in early safety evaluations. Over the course of treatment, investigators monitored participants for local reactions, systemic absorption, and treatment-emergent adverse events. While full peer-reviewed data are not publicly available, the Purdue CDEK registry confirms the methodology and population parameters.

The absence of published detailed adverse-event tables limits interpretation. Without direct access to the full dataset, we cannot determine how many participants experienced redness, itching, or other forms of irritation. This lack of transparency is an important limitation.

Phase II Trials: Findings From Men and Women

In a 24-week Phase II trial in China involving 120 men with moderate androgenetic alopecia, Kintor Pharmaceutical reported no serious adverse events and emphasized a favorable safety profile. These statements come from official filings to the Hong Kong Stock Exchange rather than peer-reviewed journals. Such filings summarize results but do not provide detailed safety breakdowns or numerical incidence of scalp reactions.

A separate 24-week Phase II trial in 160 women showed statistically significant increases in hair count at a 0.5% concentration applied once daily. Adverse events were described as mild and comparable to placebo. These results were presented in abstract form at the 2023 EADV Congress. As with the male trial, limited methodological transparency restricts our ability to critically evaluate the exact frequency and severity of scalp reactions.

Scalp Reactions Reported in Studies and Real‑World Use

The most commonly mentioned reaction across research summaries and informal user reports is mild skin irritation. This includes redness, itching, burning sensations, and slight flaking. These symptoms are consistent with the behavior of many topical solutions, especially those containing alcohol‑based vehicles.

Published summaries also mention contact dermatitis. In dermatology, contact dermatitis refers to an inflammatory skin reaction triggered either by irritation or allergy. Irritant dermatitis typically results from repeated exposure to a solution that disrupts the skin barrier, while allergic dermatitis involves an immune‑mediated response. Without detailed patch‑testing data or incidence tables, we cannot determine how common these reactions truly are in pyrilutamide users.

Community reports, while anecdotal and not verified scientifically, consistently mention temporary increases in shedding within the first weeks of use. Shedding is not documented in the sponsor’s disclosed trial data, and it is not proof that a product is working: with an unregulated product it may reflect irritation or a reaction to an unknown ingredient. New shedding, a rash or other symptoms are a reason to stop and see a doctor.

Some online users have reported systemic symptoms such as headaches or fatigue. These accounts are subjective and do not appear in any of Kintor’s disclosed data. However, they remind us that low systemic absorption does not mean zero absorption. Without peer‑reviewed pharmacokinetic data and long‑term follow‑up, it cannot be assumed that the drug has no effects beyond the scalp.

What We Still Do Not Know: The Limitations of Current Evidence

The most significant limitation in understanding pyrilutamide’s safety is the lack of complete published data. Company press releases and investor filings highlight successful endpoints but do not present full safety tables, raw adverse‑event counts, or dropout reasons. These omissions matter because safety evaluation requires detail, not summaries. Long‑term safety is also unknown. Most existing trials last 24 weeks. In March 2025 Kintor announced that an open-label 52‑week safety trial of the 0.5% tincture met its safety endpoint, with a low rate of adverse events, but the full results have not been published. Without published data covering one year or more, the possibility of chronic irritation, allergenic sensitization, or longer‑term systemic effects remains uncertain.

Furthermore, because pyrilutamide is not yet FDA‑approved, there is no publicly available FDA review detailing its safety assessments. In the absence of this, independent verification is limited.

Pyrilutamide is not approved anywhere and cannot be prescribed. Product sold online comes from unregulated research-chemical vendors, and its content and purity are unverified. The sponsor’s summaries describe mostly mild scalp reactions, but without published, peer‑reviewed adverse-event data the frequency, severity and long‑term outcomes of side effects are unknown. No reproductive-safety data on pyrilutamide have been published. Antiandrogens as a class can affect the development of a male fetus, so pyrilutamide is not considered appropriate for anyone who is pregnant, may become pregnant or is breastfeeding, and a partner who is or may be pregnant should avoid contact with treated skin. Talk to a doctor or pharmacist before using any unapproved compound.

References

Clinical Trials Center, Purdue University. (2020). NCT04502901: A study to evaluate the safety, tolerability, and pharmacokinetics of KX‑826 topical solution in healthy male subjects with androgenetic alopecia. https://cdek.pharmacy.purdue.edu/trial/NCT04502901/

European Academy of Dermatology and Venereology. (2023). EADV Congress 2023 scientific abstracts: Hair and nail disorders. https://eadv.org/wp-content/uploads/scientific-abstracts/EADV-congress-2023/Hair-and-nail-disorders.pdf

Hong Kong Stock Exchange. (2022). Kintor Pharmaceutical interim results announcement. https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0829/2022082902004.pdf

Hong Kong Stock Exchange. (2023). Kintor Pharmaceutical Phase II and Phase III clinical disclosures. https://www1.hkexnews.hk/listedco/listconews/sehk/2023/0328/2023032801491.pdf

Kintor Pharmaceutical. (2022). Phase II clinical study for KX‑826 in female androgenetic alopecia meets primary endpoint. https://www.prnewswire.com/news-releases/kintor-pharma-announced-the-primary-endpoint-of-phase-ii-clinical-study-for-kx-826s-treatment-of-female-androgenetic-alopecia-in-china-was-met-301691321.html

Kintor Pharmaceutical. (2022). KX‑826 Phase II enrollment completion announcement. https://www.prnewswire.com/news-releases/kintor-pharma-announces-completion-of-patient-enrollment-in-phase-ii-clinical-trial-of-kx-826-for-treatment-of-androgenetic-alopecia-in-the-us-301598969.html

Kintor Pharmaceutical. (2021). First patient dosed in Phase III trial of KX‑826 in China. https://en.kintor.com.cn/news_details/1803365190745829376.html

Kintor Pharmaceutical. (2025, March 20). Long-term safety Phase III clinical trial of KX-826 for the treatment of AGA reached primary endpoint (company announcement). https://en.kintor.com.cn/news_details/9.html